Keyphrases
Ciprofloxacin
100%
Israel
80%
Moxifloxacin
76%
Quinolones
50%
Caspofungin
36%
Immunomodulatory Effect
34%
Interleukin-8
32%
Cystic Fibrosis
32%
Risk Factors
31%
Interleukin-1β
27%
Israeli
26%
Candidemia
26%
Pseudomonas Aeruginosa (P. aeruginosa)
25%
Pediatric Patients
25%
Vancomycin
25%
Amphotericin B
24%
Mitogen-activated Protein Kinase
24%
Invasive Pneumococcal Disease
24%
Pharmacokinetics
24%
Antibiotics
23%
Neonatal Intensive Care Unit
21%
Fluoroquinolones
20%
Anti-inflammatory Effect
20%
Oral Administration
18%
13-valent Pneumococcal Conjugate Vaccine (PCV13)
18%
Aspergillus Fumigatus
18%
Inhibitory Effect
17%
Nationwide Survey
17%
Nuclear factor-B
17%
PCV7
17%
Cyclophosphamide
17%
Bone Marrow
16%
Kinase Activation
16%
Etoposide
16%
Escherichia Coli
16%
THP-1 Cells
16%
Candida Bloodstream Infection
16%
Pneumonia
16%
Ofloxacin
16%
VP16
16%
Aspergillus Spp
16%
Fluconazole Resistance
16%
Epithelial Cell Line
16%
Dosage Regimen
16%
Placebo-controlled Trial
16%
New Quinolone
16%
Ceftriaxone
16%
General Hospital
16%
Regulatory T Cells
16%
Magainin
16%
Pharmacology, Toxicology and Pharmaceutical Science
Ciprofloxacin
90%
Moxifloxacin
68%
Quinolone Derivative
48%
Mouse
46%
Antibiotics
33%
Cytokine
30%
Pharmacokinetics
27%
Cystic Fibrosis
24%
Fluconazole
24%
Infection
23%
Pseudomonas aeruginosa
22%
Candida
20%
Candidemia
20%
Antiinfective Agent
20%
Bloodstream Infection
20%
Tumor Necrosis Factor
19%
Nuclear Factor
18%
Antibiotic Agent
17%
Antibacterial Activity
17%
Adverse Event
17%
Alternative Complement Pathway C3 C5 Convertase
17%
Cyclophosphamide
16%
Ofloxacin
16%
Quinolone
16%
Etoposide
16%
Vancomycin
16%
Mitogen Activated Protein Kinase
16%
Pneumococcal Infection
16%
Ceftriaxone
16%
Carbapenem
16%
Placebo
16%
Ceftazidime
13%
Combination Therapy
13%
Antiinflammatory Activity
12%
DNA Topoisomerase (ATP Hydrolysing)
12%
Camptothecin
12%
Cross-Resistance
12%
Amphotericin B
11%
Interleukin 8
11%
Mitogen Activated Protein Kinase 3
11%
Bacteremia
11%
Candida Albicans
10%
Liver Enzyme
10%
Immunotherapy
10%
Antifungal Agent
10%
Interferon
10%
Interleukin 1
10%
Lipopolysaccharide
10%
Polypeptide Antibiotic Agent
10%
Aminoglycoside
10%
Medicine and Dentistry
Ciprofloxacin
32%
Infection
25%
Pediatrics
22%
Central Venous Catheter
19%
Neonatal Intensive Care Unit
18%
Candidemia
17%
Antibiotics
16%
Epithelial Cell Line
16%
Pneumococcal Infection
16%
Moxifloxacin
16%
Fluconazole
16%
Cystic Fibrosis
16%
Case-Control Study
16%
Bacteremia
14%
Diagnosis
14%
Disease
14%
Tumor Necrosis Factor
14%
Serotype
13%
Cytokine
12%
Adverse Event
12%
Antifungal Agent
11%
Secretion (Process)
11%
Mitogen-Activated Protein Kinase
11%
Mitogen Activated Protein Kinase 3
10%
Interleukin 1
10%
Neonate
10%
Nuclear Factor
10%
Bloodstream Infection
9%
Voriconazole
9%
Toddlers
9%
Cohort Effect
9%
Meningitis
9%
Candida Endocarditis
9%
Pediatrician
9%
Alternative Complement Pathway C3 C5 Convertase
9%
Neutrophil
9%
Interferon
8%
Symptom
8%
Neonatal Infant
8%
Croup
8%
Retransplantation
8%
Infectious Mononucleosis
8%
Systemic Candidiasis
8%
QT Prolongation
8%
Age Distribution
8%
Drug Dose Regimen
8%
Respiratory Tract Infection
8%
Mantoux Test
8%
Leptospira interrogans
8%
Pediatric Research
8%
